Effect of pancragen on blood glucose level, capillary permeability and adhesion in rats with experimental diabetes mellitus.
Khavinson. V Kh VKh; Gavrisheva. N A NA; Malinin. V V VV; Chefu. S G SG; Trofimov. E L EL
Key Findings
- Oral pancragen produced a clear drop in blood glucose in diabetic rats.
- Intramuscular pancragen restored normal adhesion of mesenteric capillary endothelium.
- The peptide did not affect capillary permeability in the same model.
Practical Outcomes
- For biohackers, the study hints that pancragen could be a candidate for blood‑sugar control and endothelial health, but the evidence is limited to rodents and lacks dosage, safety, and human data. Until human trials are available, it’s not ready for real‑world protocols, though it may be worth monitoring for future research.
Summary
In a rat study, the short peptide pancragen lowered blood sugar when taken by mouth and helped protect tiny blood vessels in the gut when injected into muscle. It didn't change how leaky those vessels were, but it did improve the way the vessel walls stuck together. The work suggests the peptide might have blood‑sugar‑lowering and blood‑vessel‑protecting effects early in diabetes, but it’s only been tested in animals.
Abstract
The effects of tetrapeptide pancragen (Lys-Glu-Asp-Trp-NH2) on blood glucose level and permeability and adhesion of mesenteric capillaries were studied in Wistar rats with experimental streptozotocin-induced diabetes mellitus. Oral pancragen produced a pronounced hypoglycemic effect during treatment. Intramuscular pancragen normalized the adhesion of mesenteric capillary endothelium, but did not modify capillary permeability. The results indicate homeostatic and endothelioprotective effects of pancragen during the early period of diabetes mellitus.
Study Information
pubmed
2007
2007-10-01T00:00:00.000Z
10.1007/s10517-007-0377-3
3
5